---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060444"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T01:43:10.426410+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Novavax and Sanofi enter $500M upfront collaboration; Sanofi buys $68.8M in stock

## Summary
- $500M non-refundable upfront payment; up to $700M in milestones for COVID products.
- Additional milestones up to $200M per Adjuvant Product (first four); royalties mid-single to low-twenties percent.
- Sanofi acquires 6.88M shares at $10/share (~$68.8M) in private placement.
- Sanofi gets co-exclusive rights to commercialize Novavax's COVID vaccines globally from 2025/2026 season.

## SEC filing metadata
- accession: 0001104659-24-060444
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000110465924060444/0001104659-24-060444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000110465924060444/tm2414089d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060444
- JSON: https://secwatch.observer/filing/0001104659-24-060444.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060444.txt

## Key facts
- Material Agreements
  NOVAVAX INC entered into Collaboration and License Agreement with Sanofi Pasteur Inc. valued at $500 million (effective 2024-05-10).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Sanofi Pasteur Inc.
  - Value: $500 million
  - Effective: 2024-05-10
  source text: On May 10, 2024, Novavax, Inc. (the “Company”) entered into a collaboration and license agreement (the “Collaboration and License Agreement”) with Sanofi Pasteur Inc. (“Sanofi”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1000694/000110465924060444/0001104659-24-060444-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.